Bucladesine hemicalcium (Synonyms: Dibutyryl cAMP hemicalcium; DBcAMP hemicalcium)

Name: Bucladesine hemicalcium
Brand: MedChemExpress
SKU: HY-B0764A
Rating: 5.0 (41 reviews)

Cat. No.: HY-B0764A Purity: 98.58%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Bucladesine (Dibutyryl cAMP; DBcAMP) hemicalcium is a membrane-permeable 3′, 5′-cyclic adenosine monophosphate (cAMP) analog. Bucladesine selectively activates cAMP dependent protein kinase (PKA) by increasing the intracellular level of cAMP. Bucladesine significantly attenuates MDMA-induced increases in hippocampal mitochondrial ROS formation, mitochondrial outer membrane damage, cytochrome c release, and hippocampal ADP/ATP ratio, thereby improving spatial learning and memory impairments. Bucladesine exhibit anti-nociceptive and anti-inflammation effect. Bucladesine can inhibit cancer cells proliferation, induce apoptosis. Bucladesine can be used for the researches of neurological disease, cancer, inflammation.

For research use only. We do not sell to patients.

CAS No. : 938448-87-4

Size	Stock	Quantity

Free Sample (0.1 - 0.2 mg)	Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 41 publication(s) in Google Scholar

Other Forms of Bucladesine hemicalcium:

Bucladesine sodium In-stock
Bucladesine Get quote

41 Publications Citing Use of MCE Bucladesine hemicalcium

Cell Proliferation/Viability Assay

: Bucladesine hemicalcium purchased from MedChemExpress. Usage Cited in: Int J Biol Sci. 2024 Aug 19;20(11):4476-4495. [Abstract]; The protein expression of p-AMPK (S173), p-AMPK (T172) and AMPK of HT-29 cells treated with 5-HT, either alone or in combination with H-89 (1 μM) and dbcAMP (1 μM).

: Bucladesine hemicalcium purchased from MedChemExpress. Usage Cited in: Ecotoxicol Environ Saf. 2022 Sep 15:243:113982. [Abstract]; H295R cells were treated with 30 μM BHPF in the absence or presence of 10 μM forskolin (FSK) or 100 μM dbcAMP for 48 h and evaluated by Western blotting.

: Bucladesine hemicalcium purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2022 Oct 15:932:175231. [Abstract]; B16F10 cells was pretreated or not with 3 μM Bucladesine sodium for 1 h before pterostilbene was applied for 24 h, 48h or 72 h at 3 μM. The CREB and p-CREB protein expression levels were detected by WB.

: Bucladesine hemicalcium purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2022 Oct 15:932:175231. [Abstract]; Cell viability of H295R cells exposed to 0–40 μM BHPF in the presence of 100 μM dbcAMP for 48 h.

: Bucladesine hemicalcium purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2022 Oct 15:932:175231. [Abstract]; Micrographs presenting the incorporation of EdU in H295R cells exposed to BHPF or combined with 100 μM dbcAMP for 48 h. Red: the EdU positive cells; blue: the cell nuclei (Hoechst).

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All PKA Isoform Specific Products:

View All Isoforms

PKA PKAR PKACα

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target^[1]^[4]

PKA

PDE

In Vitro

Bucladesine causes significant growth delay in multicellular tumor spheroids derived directly from human malignant brain tumors^[1].
Bucladesine augments differentiation therapy (in combination with Sodium butyrate (HY-B0350A) and hyperthermia) in human and canine brain tumor cells in vitro^[1].
Bucladesine suppresses the mitogenic effects of platelet-derived growth factor (PDGF), basic fibroblast growth factor (bFGF), and epidermal growth factor (EGF) on human astrocytoma cells; bucladesine alone neither potentiates nor inhibits human astrocytoma cell growth^[1].
Bucladesine suppresses proliferation, enhances cytoplasmic process formation, increases cytoplasmic glial fibrillary acidic protein (GFAP) levels, and suppresses malignant glioma invasion by decreasing CD44 isoform expression in cultured malignant glioma cells, inducing biochemical and morphological changes^[1].
Bucladesine decreases Bcl-2 levels and enhances SNAP-induced p53-sensitive cell death and MPP⁺-induced cell death, sensitizing human neuroblastoma cells to apoptosis^[1].
Bucladesine inhibits proliferation and induces morphological differentiation of astrocytes in vitro via a cyclic adenosine monophosphate-dependent protein kinase pathway^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Bucladesine (100 μM; bilateral intrahippocampal infusion; once daily; 4 consecutive days) significantly attenuates 3,4-methylenedioxymethamphetamine (MDMA)-induced spatial learning and memory impairments and hippocampal mitochondrial dysfunction in adult male Wistar rats^[2].
Bucladesine (50-300 nM/mouse; i.p.; single dose) exerts a biphasic anti-nociceptive effect on thermal-induced acute pain in male albino mice, with significant activity at 50 and 100 nM/mouse doses, no significant effect at 300 nM/mouse^[3].
Bucladesine (0.5-1.5% cream, 5% solution; topical; single or two doses) produces a statistically significant reduction in Arachidonic acid (HY-109590)-induced acute skin inflammation in Mus musculus, with single administration of 1.5% cream yielding a 28% reduction in ear swelling and two administrations yielding a 24% reduction^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

489.43

Formula

C₁₈H₂₄N₅O₈P·1/2Na

CAS No.

938448-87-4

Appearance

Solid

Color

White to off-white

SMILES

O=C(CCC)O[C@H]1[C@H](N2C(N=CN=C3NC(CCC)=O)=C3N=C2)O[C@@](CO4)([H])[C@@]1([H])OP4([O-])=O.[Ca2+]

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

H₂O : 100 mg/mL (204.32 mM; Need ultrasonic)

DMSO : 100 mg/mL (204.32 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.0432 mL	10.2160 mL	20.4319 mL
5 mM	0.4086 mL	2.0432 mL	4.0864 mL
10 mM	0.2043 mL	1.0216 mL	2.0432 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.11 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (5.11 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (5.11 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS
Solubility: 110 mg/mL (224.75 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).

Purity & Documentation

Purity: 98.58%

Select Batch:

Data Sheet (282 KB) SDS (252 KB)

COA (252 KB) HNMR (360 KB) RP-HPLC (266 KB) LCMS (93 KB)

Handling Instructions (2659 KB)

References

[1]. Dalbasti T, et al. Local interstitial chemotherapy with sustained release bucladesine in de novo glioblastoma multiforme: a preliminary study. J Neurooncol. 2002;56(2):167-174.

[2]. Taghizadeh G, et al. Bucladesine Attenuates Spatial Learning and Hippocampal Mitochondrial Impairments Induced by 3, 4-Methylenedioxymethamphetamine (MDMA). Neurotox Res. 2020;38(1):38-49.

[3]. Salehi F, et al. Effect of bucladesine, pentoxifylline, and H-89 as cyclic adenosine monophosphate analog, phosphodiesterase, and protein kinase A inhibitor on acute pain. Fundam Clin Pharmacol. 2017;31(4):411-419. [Content Brief]

[4]. Rundfeldt C, et al. The stable cyclic adenosine monophosphate analogue, dibutyryl cyclo-adenosine monophosphate (bucladesine), is active in a model of acute skin inflammation. Arch Dermatol Res. 2012;304(4):313-317. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

H₂O / DMSO	1 mM	2.0432 mL	10.2160 mL	20.4319 mL	51.0798 mL
	5 mM	0.4086 mL	2.0432 mL	4.0864 mL	10.2160 mL
	10 mM	0.2043 mL	1.0216 mL	2.0432 mL	5.1080 mL
	15 mM	0.1362 mL	0.6811 mL	1.3621 mL	3.4053 mL
	20 mM	0.1022 mL	0.5108 mL	1.0216 mL	2.5540 mL
	25 mM	0.0817 mL	0.4086 mL	0.8173 mL	2.0432 mL
	30 mM	0.0681 mL	0.3405 mL	0.6811 mL	1.7027 mL
	40 mM	0.0511 mL	0.2554 mL	0.5108 mL	1.2770 mL
	50 mM	0.0409 mL	0.2043 mL	0.4086 mL	1.0216 mL
	60 mM	0.0341 mL	0.1703 mL	0.3405 mL	0.8513 mL
	80 mM	0.0255 mL	0.1277 mL	0.2554 mL	0.6385 mL
	100 mM	0.0204 mL	0.1022 mL	0.2043 mL	0.5108 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Bucladesine hemicalcium Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Bucladesine hemicalcium938448-87-4Dibutyryl cAMP hemicalcium DBcAMP hemicalciumPKAApoptosisReactive Oxygen Species (ROS)Protein kinase AInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Bucladesine hemicalcium (Synonyms: Dibutyryl cAMP hemicalcium; DBcAMP hemicalcium)

Customer Review

Other Forms of Bucladesine hemicalcium:

Bucladesine hemicalcium Related Antibodies

41 Publications Citing Use of MCE Bucladesine hemicalcium

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All PKA Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Bucladesine hemicalcium Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Bucladesine hemicalcium Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report